Prospective Pilot Study for the Evaluation of Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Liver Transplant Candidates (ESGiTX)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Liver Transplantation; Bariatric Surgery; Obesity

Treatments: Procedure: Endoscopic sleeve gastroplasty (ESG)

Study type: Interventional

Funder types: Other

Identifiers

NCT05760235

4903

Details and patient eligibility

About

The goal of this pilot prospective interventional study is to evaluate the efficacy of endoscopic sleeve gastroplasty (ESG) in allowing obese subjects with the need of liver transplantation to reduce their BMI in order to enter the waiting list (BMI (≥35 kg/m2). The main question[s] it aims to answer are:

• Is the procedure effective in reducing BMI to the target level in 12 months?
• Which is the effect on weight loss, quality of life and obesity-related comorbidities?

Participants will undergo ESG as per standard clinical practice and followed up to 12 months before transplantation and for 12 months after transplantation

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (i.e., age between 18 and 70 years).
• BMI ≥ 35 kg/m²;
• Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2);
• Signed informed consent.

Exclusion criteria

• Clinically significant portal hypertension at upper endoscopy: F3 or F1/F2 with red signs oesophageal varices, gastric varices or severe hypertensive gastropathy;
• Upper gastro-intestinal bleeding (gastric or esophageal) in the previous six months;
• CHILD C class;
• Clinically or ultrasound-detected ascites in the 15 days before the procedure. Only mild ascitic effusion in the pelvis will be accepted;
• Spontaneous bacterial peritonitis in the previous 6 months;
• Hepatocellular carcinoma with extra hepatic spread;
• Previous stomach, oesophagus or duodenum surgery;
• Technical non-feasibility in the opinion of the endoscopist;
• Clinical signs of active infection;
• Unstable cardiac disease or chronic heart failure;
• Platelet count less than 70.000;
• International Normalized Ratio ≥ 1,5;
• Concomitant unstoppable anticoagulant or anti platelet therapy, except for low dose aspirin (≤ 100 mg);
• Acute liver failure;
• Easy to bleed during diagnostic endoscopy;
• Active drugs or alcohol abuse;
• Pregnancy, lactation (desire to become pregnant during study duration);
• Enrolment in other clinical studies;
• Contraindication to general anaesthesia;
• Contraindication to endoscopic procedure;
• Other conditions to exclude the subject in investigators opinion;
• Refusal to sign informed consent.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Liver transplant obese candidates

Experimental group

Description:

Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)

Treatment:

Procedure: Endoscopic sleeve gastroplasty (ESG)